HAIC-FO improves outcomes in HCC
- PMID: 35013583
- DOI: 10.1038/s41571-022-00599-0
HAIC-FO improves outcomes in HCC
Comment on
-
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).J Clin Oncol. 2022 Feb 10;40(5):468-480. doi: 10.1200/JCO.21.01963. Epub 2021 Dec 14. J Clin Oncol. 2022. PMID: 34905388 Clinical Trial.
References
Original article
-
- Lyu, N. et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J. Clin Oncol https://doi.org/10.1200/JCO.21.01963 (2021) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
